Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

KATHERINE B REED

Allopathic & Osteopathic Physicians Dermatology

NPI
1396919569
CMS profile
335358
Location
SPOKANE, WA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2025 · Entire year

$1,169.72

67 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2025 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $1,169.72 67

By paying entity

PY2025 · entire year · sorted by reported total

Page 1 of 2; records 1–50 of 67 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

KATHERINE B REED

NPI 1396919569 · CMS profile ID 335358

Allopathic & Osteopathic Physicians / Dermatology

SPOKANE, WA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 2; records 1–50 of 67 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1396919569?year=2025&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
KATHERINE B REED, NPI 1396919569, CMS profile ID 335358. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 2; records 1–50 of 67 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1396919569?year=2025&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
APA 7
IndustryPayments. (2026). KATHERINE B REED, NPI 1396919569, CMS profile ID 335358. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 2; records 1–50 of 67 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1396919569?year=2025&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
Bluebook
KATHERINE B REED, NPI 1396919569, CMS profile ID 335358, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 2; records 1–50 of 67 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1396919569?year=2025&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30

67 matching records · $1,169.72 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 67 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–50 of 67.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Incyte Corporation $17.4312/18/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1226024420 CMS
LEO Pharma Inc. $24.9912/03/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1252030946 CMS
LEO Pharma Inc. $24.9912/03/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1252030948 CMS
ABBVIE INC. $17.3912/01/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1203812101 CMS
Galderma Laboratories, L.P. $22.1111/18/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1234693533 CMS
PFIZER INC. $22.6311/18/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1229607458 CMS
Galderma Laboratories, L.P. $1.7711/17/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1234693531 CMS
GENZYME CORPORATION $26.6411/12/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1233409599 CMS
Janssen Biotech, Inc. $12.3411/11/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1175334835 CMS
ABBVIE INC. $29.9711/05/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1203812094 CMS
Regeneron Healthcare Solutions, Inc. $19.5310/21/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1213022227 CMS
Incyte Corporation $20.0110/16/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1226189751 CMS
Lilly USA, LLC $20.1910/15/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1186663547 CMS
UCB, Inc. $14.2310/03/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1224618639 CMS
Galderma Laboratories, L.P. $1.5210/02/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1234693529 CMS
Galderma Laboratories, L.P. $15.3210/01/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1234693527 CMS
Janssen Biotech, Inc. $11.1509/24/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1175336046 CMS
Janssen Biotech, Inc. $3.7809/24/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1175338418 CMS
SUN PHARMACEUTICAL INDUSTRIES INC. $32.0109/23/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1251018402 CMS
Organon LLC $18.4309/15/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1237706496 CMS
Lilly USA, LLC $22.0109/10/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1186671111 CMS
Janssen Biotech, Inc. $14.0009/09/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1175335549 CMS
Janssen Biotech, Inc. $17.9609/02/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1175334877 CMS
Galderma Laboratories, L.P. $17.0208/21/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1234693523 CMS
Galderma Laboratories, L.P. $1.5208/21/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1234693525 CMS
Lilly USA, LLC $24.7208/20/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1186702839 CMS
ABBVIE INC. $24.4008/12/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1203812087 CMS
GENZYME CORPORATION $25.7508/05/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1233409567 CMS
Janssen Biotech, Inc. $14.5407/29/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1175338727 CMS
Arcutis Biotherapeutics, Inc. $16.7607/28/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1252353115 CMS
Galderma Laboratories, L.P. $24.7207/25/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1234693521 CMS
Galderma Laboratories, L.P. $1.6607/24/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1234693519 CMS
ABBVIE INC. $31.7107/15/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1203812082 CMS
Lilly USA, LLC $21.4607/15/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1186663545 CMS
Janssen Biotech, Inc. $15.2007/08/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1175335302 CMS
ABBVIE INC. $18.0406/24/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1203812075 CMS
Galderma Laboratories, L.P. $18.2406/18/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1234693515 CMS
Galderma Laboratories, L.P. $1.7406/18/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1234693517 CMS
GENZYME CORPORATION $25.1606/11/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1233409545 CMS
Lilly USA, LLC $17.2305/28/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1186683309 CMS
ABBVIE INC. $14.5705/19/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1203812070 CMS
Galderma Laboratories, L.P. $1.7405/15/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1234693511 CMS
Galderma Laboratories, L.P. $22.2405/15/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1234693513 CMS
Janssen Biotech, Inc. $26.3205/13/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1175333969 CMS
Amgen Inc. $27.0005/01/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1228688104 CMS
Lilly USA, LLC $23.9004/24/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1186671115 CMS
Galderma Laboratories, L.P. $4.6504/17/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1234693509 CMS
Galderma Laboratories, L.P. $6.1204/16/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1234693507 CMS
Novartis Pharmaceuticals Corporation $17.8004/04/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1200545782 CMS
ABBVIE INC. $17.0104/03/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1203812063 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $547.33 32
PY2020 $413.54 18
PY2021 $570.86 34
PY2022 $538.17 34
PY2023 $498.08 30
PY2024 $705.53 35
PY2025 $1,169.72 67

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $734,267.33 246
PY2024 Principal investigator $853,745.12 356
PY2023 Principal investigator $644,757.85 253
PY2022 Principal investigator $361,336.03 142
PY2021 Principal investigator $277,998.71 117
PY2020 Principal investigator $149,365.00 24
PY2019 Principal investigator $53,682.69 24

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

246 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Incyte Corporation $1,976.00 12/19/2025 Non-covered Recipient Entity
INNOVATIVE CLINICAL RESEARCH INSTITUTE
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240539310
Principal investigator 1 Incyte Corporation $1,976.00 12/19/2025 Non-covered Recipient Entity
INNOVATIVE CLINICAL RESEARCH INSTITUTE
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240539314
Principal investigator 1 Incyte Corporation $2,247.00 12/19/2025 Non-covered Recipient Entity
INNOVATIVE CLINICAL RESEARCH INSTITUTE
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240539326
Principal investigator 1 Incyte Corporation $1,391.00 12/19/2025 Non-covered Recipient Entity
INNOVATIVE CLINICAL RESEARCH INSTITUTE
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240539330
Principal investigator 1 Incyte Corporation $1,391.00 12/19/2025 Non-covered Recipient Entity
INNOVATIVE CLINICAL RESEARCH INSTITUTE
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240539333
Principal investigator 1 Incyte Corporation $1,391.00 12/19/2025 Non-covered Recipient Entity
INNOVATIVE CLINICAL RESEARCH INSTITUTE
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240539338
Principal investigator 1 Incyte Corporation $1,427.00 12/19/2025 Non-covered Recipient Entity
INNOVATIVE CLINICAL RESEARCH INSTITUTE
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240539356
Principal investigator 1 Incyte Corporation $1,433.00 12/19/2025 Non-covered Recipient Entity
INNOVATIVE CLINICAL RESEARCH INSTITUTE
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240539358
Principal investigator 1 Incyte Corporation $1,064.00 12/19/2025 Non-covered Recipient Entity
INNOVATIVE CLINICAL RESEARCH INSTITUTE
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240539396
Principal investigator 1 Incyte Corporation $1,183.00 12/19/2025 Non-covered Recipient Entity
INNOVATIVE CLINICAL RESEARCH INSTITUTE
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240539400
Principal investigator 1 Incyte Corporation $1,183.00 12/19/2025 Non-covered Recipient Entity
INNOVATIVE CLINICAL RESEARCH INSTITUTE
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240539404
Principal investigator 1 Incyte Corporation $1,613.00 12/19/2025 Non-covered Recipient Entity
INNOVATIVE CLINICAL RESEARCH INSTITUTE
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240539424
Principal investigator 1 Incyte Corporation $1,613.00 12/19/2025 Non-covered Recipient Entity
INNOVATIVE CLINICAL RESEARCH INSTITUTE
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240539428
Principal investigator 1 Incyte Corporation $1,613.00 12/19/2025 Non-covered Recipient Entity
INNOVATIVE CLINICAL RESEARCH INSTITUTE
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240539432
Principal investigator 1 Incyte Corporation $46.00 12/19/2025 Non-covered Recipient Entity
INNOVATIVE CLINICAL RESEARCH INSTITUTE
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240539522
Principal investigator 1 Incyte Corporation $46.00 12/19/2025 Non-covered Recipient Entity
INNOVATIVE CLINICAL RESEARCH INSTITUTE
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240539525
Principal investigator 1 Incyte Corporation $46.00 12/19/2025 Non-covered Recipient Entity
INNOVATIVE CLINICAL RESEARCH INSTITUTE
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240539529
Principal investigator 1 Incyte Corporation $46.00 12/19/2025 Non-covered Recipient Entity
INNOVATIVE CLINICAL RESEARCH INSTITUTE
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240539533
Principal investigator 1 Incyte Corporation $46.00 12/19/2025 Non-covered Recipient Entity
INNOVATIVE CLINICAL RESEARCH INSTITUTE
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240539537
Principal investigator 1 Incyte Corporation $46.00 12/19/2025 Non-covered Recipient Entity
INNOVATIVE CLINICAL RESEARCH INSTITUTE
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240539541
Principal investigator 1 Incyte Corporation $46.00 12/19/2025 Non-covered Recipient Entity
INNOVATIVE CLINICAL RESEARCH INSTITUTE
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240539545
Principal investigator 1 Incyte Corporation $46.00 12/19/2025 Non-covered Recipient Entity
INNOVATIVE CLINICAL RESEARCH INSTITUTE
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240539549
Principal investigator 1 Incyte Corporation $1,469.00 12/19/2025 Non-covered Recipient Entity
INNOVATIVE CLINICAL RESEARCH INSTITUTE
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240539557
Principal investigator 1 Incyte Corporation $1,538.00 12/19/2025 Non-covered Recipient Entity
INNOVATIVE CLINICAL RESEARCH INSTITUTE
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240539561
Principal investigator 1 Incyte Corporation $1,538.00 12/19/2025 Non-covered Recipient Entity
INNOVATIVE CLINICAL RESEARCH INSTITUTE
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240539566
Principal investigator 1 PFIZER INC. $552.97 12/19/2025 Non-covered Recipient Entity
Dermatology Specialists of Spokane
A PHASE 3 EXTERNAL AND SYNTHETIC PLACEBOCONTROLLED RANDOMIZED STUDY WITH DOSEUP FOR NONRESPONDERS TO INVESTIGATE SAFETY AND EFFICACY OF RITLECITINIB 50 MG AND 100 MG ONCE DAILY IN ADULT AND ADOLESCENT PARTICIPANTS 12 YEARS OF AGE AND OLDER WITH ALOPECIA AREATA No dispute reported 06/30/2026 1228725792
Principal investigator 1 Incyte Corporation $688.00 12/17/2025 Non-covered Recipient Entity
INNOVATIVE CLINICAL RESEARCH INSTITUTE
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240539392
Principal investigator 1 Incyte Corporation $138.00 12/17/2025 Non-covered Recipient Entity
INNOVATIVE CLINICAL RESEARCH INSTITUTE
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240539469
Principal investigator 1 Incyte Corporation $152.00 12/17/2025 Non-covered Recipient Entity
INNOVATIVE CLINICAL RESEARCH INSTITUTE
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240539489
Principal investigator 1 Incyte Corporation $2,760.00 12/17/2025 Non-covered Recipient Entity
INNOVATIVE CLINICAL RESEARCH INSTITUTE
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240539505
Principal investigator 1 PFIZER INC. $4,372.66 12/11/2025 Non-covered Recipient Entity
Dermatology Specialists of Spokane
A PHASE 3 EXTERNAL AND SYNTHETIC PLACEBOCONTROLLED RANDOMIZED STUDY WITH DOSEUP FOR NONRESPONDERS TO INVESTIGATE SAFETY AND EFFICACY OF RITLECITINIB 50 MG AND 100 MG ONCE DAILY IN ADULT AND ADOLESCENT PARTICIPANTS 12 YEARS OF AGE AND OLDER WITH ALOPECIA AREATA No dispute reported 06/30/2026 1228747037
Principal investigator 1 Incyte Corporation $9,934.00 12/08/2025 Non-covered Recipient Entity
INNOVATIVE CLINICAL RESEARCH INSTITUTE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240539476
Principal investigator 1 ABBVIE INC. $17,793.10 12/04/2025 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202527824
Principal investigator 1 Incyte Corporation $666.50 12/04/2025 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib No dispute reported 06/30/2026 1240526939
Principal investigator 1 Incyte Corporation $2,139.00 12/04/2025 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240527063
Principal investigator 1 Incyte Corporation $2.37 12/01/2025 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240526942
Principal investigator 1 Incyte Corporation $2.37 12/01/2025 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240526946
Principal investigator 1 Incyte Corporation $2.37 12/01/2025 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240526950
Principal investigator 1 Incyte Corporation $49.77 12/01/2025 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240526954
Principal investigator 1 Incyte Corporation $18.96 12/01/2025 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240526957
Principal investigator 1 Incyte Corporation $9.48 12/01/2025 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240526961
Principal investigator 1 Incyte Corporation $9.48 12/01/2025 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240526965
Principal investigator 1 Incyte Corporation $11.85 12/01/2025 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240526969
Principal investigator 1 Incyte Corporation $16.59 12/01/2025 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240526979
Principal investigator 1 Incyte Corporation $7.11 12/01/2025 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240526984
Principal investigator 1 Incyte Corporation $7.11 12/01/2025 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240526988
Principal investigator 1 Incyte Corporation $47.40 12/01/2025 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240526992
Principal investigator 1 Incyte Corporation $47.40 12/01/2025 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240526997
Principal investigator 1 Incyte Corporation $1.02 12/01/2025 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240527001
Principal investigator 1 Incyte Corporation $4.74 12/01/2025 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240527005
Principal investigator 1 Incyte Corporation $78.00 11/21/2025 Non-covered Recipient Entity
INNOVATIVE CLINICAL RESEARCH INSTITUTE
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240539306
Principal investigator 1 Incyte Corporation $1,469.00 11/21/2025 Non-covered Recipient Entity
INNOVATIVE CLINICAL RESEARCH INSTITUTE
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240539342
Principal investigator 1 Incyte Corporation $1,469.00 11/21/2025 Non-covered Recipient Entity
INNOVATIVE CLINICAL RESEARCH INSTITUTE
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240539345
Principal investigator 1 Incyte Corporation $1,469.00 11/21/2025 Non-covered Recipient Entity
INNOVATIVE CLINICAL RESEARCH INSTITUTE
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240539348
Principal investigator 1 Incyte Corporation $1,538.00 11/21/2025 Non-covered Recipient Entity
INNOVATIVE CLINICAL RESEARCH INSTITUTE
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240539352
Principal investigator 1 Incyte Corporation $1,505.00 11/21/2025 Non-covered Recipient Entity
INNOVATIVE CLINICAL RESEARCH INSTITUTE
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240539363
Principal investigator 1 Incyte Corporation $1,505.00 11/21/2025 Non-covered Recipient Entity
INNOVATIVE CLINICAL RESEARCH INSTITUTE
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240539367
Principal investigator 1 Incyte Corporation $1,505.00 11/21/2025 Non-covered Recipient Entity
INNOVATIVE CLINICAL RESEARCH INSTITUTE
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240539371
Principal investigator 1 Incyte Corporation $1,613.00 11/21/2025 Non-covered Recipient Entity
INNOVATIVE CLINICAL RESEARCH INSTITUTE
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240539408
Principal investigator 1 Incyte Corporation $2,247.00 11/21/2025 Non-covered Recipient Entity
INNOVATIVE CLINICAL RESEARCH INSTITUTE
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240539450
Principal investigator 1 Incyte Corporation $2,247.00 11/21/2025 Non-covered Recipient Entity
INNOVATIVE CLINICAL RESEARCH INSTITUTE
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240539456
Principal investigator 1 Incyte Corporation $2,247.00 11/21/2025 Non-covered Recipient Entity
INNOVATIVE CLINICAL RESEARCH INSTITUTE
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240539460
Principal investigator 1 Incyte Corporation $46.00 11/21/2025 Non-covered Recipient Entity
INNOVATIVE CLINICAL RESEARCH INSTITUTE
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240539514
Principal investigator 1 Incyte Corporation $46.00 11/21/2025 Non-covered Recipient Entity
INNOVATIVE CLINICAL RESEARCH INSTITUTE
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240539518
Principal investigator 1 PFIZER INC. $5,186.70 11/18/2025 Non-covered Recipient Entity
Dermatology Specialists of Spokane
A PHASE 3 EXTERNAL AND SYNTHETIC PLACEBOCONTROLLED RANDOMIZED STUDY WITH DOSEUP FOR NONRESPONDERS TO INVESTIGATE SAFETY AND EFFICACY OF RITLECITINIB 50 MG AND 100 MG ONCE DAILY IN ADULT AND ADOLESCENT PARTICIPANTS 12 YEARS OF AGE AND OLDER WITH ALOPECIA AREATA No dispute reported 06/30/2026 1228737817
Principal investigator 1 Incyte Corporation $2,512.80 11/13/2025 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib No dispute reported 06/30/2026 1240526935
Principal investigator 1 ABBVIE INC. $11,676.40 11/05/2025 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202522423
Principal investigator 1 PFIZER INC. $5,186.70 10/31/2025 Non-covered Recipient Entity
Dermatology Specialists of Spokane
A PHASE 3 EXTERNAL AND SYNTHETIC PLACEBOCONTROLLED RANDOMIZED STUDY WITH DOSEUP FOR NONRESPONDERS TO INVESTIGATE SAFETY AND EFFICACY OF RITLECITINIB 50 MG AND 100 MG ONCE DAILY IN ADULT AND ADOLESCENT PARTICIPANTS 12 YEARS OF AGE AND OLDER WITH ALOPECIA AREATA No dispute reported 06/30/2026 1228741963
Principal investigator 1 ABBVIE INC. $1,167.40 10/30/2025 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202519671
Principal investigator 1 ABBVIE INC. $1,517.10 10/30/2025 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202519673
Principal investigator 1 Incyte Corporation $1,894.00 10/29/2025 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240527059
Principal investigator 1 Incyte Corporation $46.00 10/22/2025 Non-covered Recipient Entity
INNOVATIVE CLINICAL RESEARCH INSTITUTE
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240539318
Principal investigator 1 Incyte Corporation $46.00 10/22/2025 Non-covered Recipient Entity
INNOVATIVE CLINICAL RESEARCH INSTITUTE
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240539322
Principal investigator 1 Incyte Corporation $1,613.00 10/22/2025 Non-covered Recipient Entity
INNOVATIVE CLINICAL RESEARCH INSTITUTE
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240539376
Principal investigator 1 Incyte Corporation $1,613.00 10/22/2025 Non-covered Recipient Entity
INNOVATIVE CLINICAL RESEARCH INSTITUTE
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240539380
Principal investigator 1 Incyte Corporation $78.00 10/22/2025 Non-covered Recipient Entity
INNOVATIVE CLINICAL RESEARCH INSTITUTE
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240539384
Principal investigator 1 Incyte Corporation $78.00 10/22/2025 Non-covered Recipient Entity
INNOVATIVE CLINICAL RESEARCH INSTITUTE
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240539388
Principal investigator 1 Incyte Corporation $1,538.00 10/22/2025 Non-covered Recipient Entity
INNOVATIVE CLINICAL RESEARCH INSTITUTE
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240539412
Principal investigator 1 Incyte Corporation $1,538.00 10/22/2025 Non-covered Recipient Entity
INNOVATIVE CLINICAL RESEARCH INSTITUTE
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240539417
Principal investigator 1 Incyte Corporation $1,538.00 10/22/2025 Non-covered Recipient Entity
INNOVATIVE CLINICAL RESEARCH INSTITUTE
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240539420
Principal investigator 1 Incyte Corporation $2,247.00 10/22/2025 Non-covered Recipient Entity
INNOVATIVE CLINICAL RESEARCH INSTITUTE
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240539442
Principal investigator 1 Incyte Corporation $2,247.00 10/22/2025 Non-covered Recipient Entity
INNOVATIVE CLINICAL RESEARCH INSTITUTE
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240539446
Principal investigator 1 Incyte Corporation $69.00 10/22/2025 Non-covered Recipient Entity
INNOVATIVE CLINICAL RESEARCH INSTITUTE
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240539465
Principal investigator 1 Incyte Corporation $1,469.00 10/22/2025 Non-covered Recipient Entity
INNOVATIVE CLINICAL RESEARCH INSTITUTE
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240539480
Principal investigator 1 Incyte Corporation $1,469.00 10/22/2025 Non-covered Recipient Entity
INNOVATIVE CLINICAL RESEARCH INSTITUTE
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240539485
Principal investigator 1 Incyte Corporation $197.00 10/22/2025 Non-covered Recipient Entity
INNOVATIVE CLINICAL RESEARCH INSTITUTE
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240539501
Principal investigator 1 Incyte Corporation $72.00 10/22/2025 Non-covered Recipient Entity
INNOVATIVE CLINICAL RESEARCH INSTITUTE
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240539570
Principal investigator 1 Incyte Corporation $688.00 10/20/2025 Non-covered Recipient Entity
INNOVATIVE CLINICAL RESEARCH INSTITUTE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240539553
Principal investigator 1 ABBVIE INC. $991.90 10/09/2025 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202513691
Principal investigator 1 ABBVIE INC. $12,838.90 10/09/2025 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202516285
Principal investigator 1 Incyte Corporation $2,484.00 10/08/2025 Non-covered Recipient Entity
INNOVATIVE CLINICAL RESEARCH INSTITUTE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240539473
Principal investigator 1 Incyte Corporation $1,996.00 10/08/2025 Non-covered Recipient Entity
INNOVATIVE CLINICAL RESEARCH INSTITUTE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240539497
Principal investigator 1 Incyte Corporation $846.00 10/03/2025 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib No dispute reported 06/30/2026 1240526927
Principal investigator 1 Incyte Corporation $393.00 10/03/2025 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib No dispute reported 06/30/2026 1240526931
Principal investigator 1 Incyte Corporation $1,620.00 10/02/2025 Non-covered Recipient Entity
INNOVATIVE CLINICAL RESEARCH INSTITUTE
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240539438
Principal investigator 1 Incyte Corporation $2,000.70 10/02/2025 Non-covered Recipient Entity
INNOVATIVE CLINICAL RESEARCH INSTITUTE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240539493
Principal investigator 1 Incyte Corporation $1,500.00 10/02/2025 Non-covered Recipient Entity
INNOVATIVE CLINICAL RESEARCH INSTITUTE
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240539510
Principal investigator 1 ABBVIE INC. $972.84 09/25/2025 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202512196
Principal investigator 1 ABBVIE INC. $1,400.00 09/25/2025 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202512198
Principal investigator 1 Incyte Corporation $1,613.00 09/25/2025 Non-covered Recipient Entity
INNOVATIVE CLINICAL RESEARCH INSTITUTE
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240539229
Principal investigator 1 Incyte Corporation $1,613.00 09/25/2025 Non-covered Recipient Entity
INNOVATIVE CLINICAL RESEARCH INSTITUTE
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240539233
Principal investigator 1 Incyte Corporation $2,247.00 09/25/2025 Non-covered Recipient Entity
INNOVATIVE CLINICAL RESEARCH INSTITUTE
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240539237
Principal investigator 1 Incyte Corporation $46.00 09/25/2025 Non-covered Recipient Entity
INNOVATIVE CLINICAL RESEARCH INSTITUTE
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240539241
Principal investigator 1 Incyte Corporation $78.00 09/25/2025 Non-covered Recipient Entity
INNOVATIVE CLINICAL RESEARCH INSTITUTE
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240539244
Principal investigator 1 Incyte Corporation $78.00 09/25/2025 Non-covered Recipient Entity
INNOVATIVE CLINICAL RESEARCH INSTITUTE
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240539249
Principal investigator 1 Incyte Corporation $2,247.00 09/25/2025 Non-covered Recipient Entity
INNOVATIVE CLINICAL RESEARCH INSTITUTE
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240539256
Principal investigator 1 Incyte Corporation $2,247.00 09/25/2025 Non-covered Recipient Entity
INNOVATIVE CLINICAL RESEARCH INSTITUTE
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240539261
Principal investigator 1 Incyte Corporation $1,469.00 09/25/2025 Non-covered Recipient Entity
INNOVATIVE CLINICAL RESEARCH INSTITUTE
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240539290
Principal investigator 1 Incyte Corporation $1,613.00 09/25/2025 Non-covered Recipient Entity
INNOVATIVE CLINICAL RESEARCH INSTITUTE
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240539295
Principal investigator 1 Incyte Corporation $78.00 09/25/2025 Non-covered Recipient Entity
INNOVATIVE CLINICAL RESEARCH INSTITUTE
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240539302
Principal investigator 1 PFIZER INC. $13,835.00 09/24/2025 Non-covered Recipient Entity
Dermatology Specialists of Spokane
A PHASE 3 EXTERNAL AND SYNTHETIC PLACEBOCONTROLLED RANDOMIZED STUDY WITH DOSEUP FOR NONRESPONDERS TO INVESTIGATE SAFETY AND EFFICACY OF RITLECITINIB 50 MG AND 100 MG ONCE DAILY IN ADULT AND ADOLESCENT PARTICIPANTS 12 YEARS OF AGE AND OLDER WITH ALOPECIA AREATA No dispute reported 06/30/2026 1228743300
Principal investigator 1 Incyte Corporation $1,161.90 09/23/2025 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib No dispute reported 06/30/2026 1240526914
Principal investigator 1 Incyte Corporation $1,000.00 09/15/2025 Non-covered Recipient Entity
INNOVATIVE CLINICAL RESEARCH INSTITUTE
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240539252
Principal investigator 1 Incyte Corporation $11,500.00 09/15/2025 Non-covered Recipient Entity
INNOVATIVE CLINICAL RESEARCH INSTITUTE
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240539265
Principal investigator 1 Incyte Corporation $2,000.00 09/15/2025 Non-covered Recipient Entity
INNOVATIVE CLINICAL RESEARCH INSTITUTE
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240539270
Principal investigator 1 ABBVIE INC. $13,345.60 09/04/2025 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202508484
Principal investigator 1 Incyte Corporation $3,634.00 08/26/2025 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240527050
Principal investigator 1 Incyte Corporation $172.00 08/22/2025 Non-covered Recipient Entity
INNOVATIVE CLINICAL RESEARCH INSTITUTE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240539274
Principal investigator 1 Incyte Corporation $1,161.90 08/21/2025 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib No dispute reported 06/30/2026 1240526910
Principal investigator 1 Incyte Corporation $755.54 08/21/2025 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240527055
Principal investigator 1 Incyte Corporation $856.00 08/20/2025 Non-covered Recipient Entity
INNOVATIVE CLINICAL RESEARCH INSTITUTE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240539282
Principal investigator 1 Incyte Corporation $1,500.00 08/20/2025 Non-covered Recipient Entity
INNOVATIVE CLINICAL RESEARCH INSTITUTE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240539286
Principal investigator 1 ABBVIE INC. $27,558.50 08/06/2025 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202503281
Principal investigator 1 SANOFI US SERVICES INC. $10,000.00 08/06/2025 Non-covered Recipient Entity
Dermatology Specialists Of Spokane
A Parallel-group Treatment, Phase 2, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of SAR444656 in Adult Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1226097305
Principal investigator 1 SANOFI US SERVICES INC. $2,000.00 08/06/2025 Non-covered Recipient Entity
Dermatology Specialists Of Spokane
A Parallel-group Treatment, Phase 2, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of SAR444656 in Adult Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1226097312
Principal investigator 1 Incyte Corporation $59.13 08/04/2025 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240526918
Principal investigator 1 Incyte Corporation $59.13 08/04/2025 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240526923
Principal investigator 1 ABBVIE INC. $1,314.30 07/31/2025 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202500578
Principal investigator 1 Incyte Corporation $107.00 07/31/2025 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib No dispute reported 06/30/2026 1240526902
Principal investigator 1 Organon Llc $4,732.00 07/28/2025 Non-covered Recipient Entity
Dermatology Specialists Of Spk-Svip
Tapinarof for the Treatment of Plaque Psoriasis in Pediatric Subjects No dispute reported 06/30/2026 1173042810
Principal investigator 1 SANOFI US SERVICES INC. $4,986.00 07/25/2025 Non-covered Recipient Entity
Dermatology Specialists Of Spokane
A Parallel-group Treatment, Phase 2, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of SAR444656 in Adult Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1226097318
Principal investigator 1 SANOFI US SERVICES INC. $3,750.00 07/23/2025 Non-covered Recipient Entity
Dermatology Specialists Of Spokane
A Parallel-group Treatment, Phase 2, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of SAR444656 in Adult Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1226097324
Principal investigator 1 Incyte Corporation $1,707.00 07/22/2025 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240527046
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $9,000.00 07/18/2025 Non-covered Recipient Entity
Dermatology Specialists Of Spokane
Randomised, double-blind, placebo-controlled, Phase IIb/Phase III study to evaluate the efficacy and safety of spesolimab in patients with moderate to severe hidradenitis suppurativa. Lunsayil 1. No dispute reported 06/30/2026 1220795085
Principal investigator 1 Incyte Corporation $1,127.70 07/18/2025 Non-covered Recipient Entity
INNOVATIVE CLINICAL RESEARCH INSTITUTE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240539278
Principal investigator 1 Incyte Corporation $2,223.00 07/18/2025 Non-covered Recipient Entity
INNOVATIVE CLINICAL RESEARCH INSTITUTE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240539299
Principal investigator 1 Incyte Corporation $4,005.00 07/17/2025 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240527042
Principal investigator 1 ABBVIE INC. $41.88 07/10/2025 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202497794
Principal investigator 1 Incyte Corporation $1,161.90 07/04/2025 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib No dispute reported 06/30/2026 1240526906
Principal investigator 1 ABBVIE INC. $13,849.10 07/02/2025 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202494207
Principal investigator 1 Incyte Corporation $768.30 06/25/2025 Non-covered Recipient Entity
INNOVATIVE CLINICAL RESEARCH INSTITUTE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240539184
Principal investigator 1 Incyte Corporation $2,223.00 06/25/2025 Non-covered Recipient Entity
INNOVATIVE CLINICAL RESEARCH INSTITUTE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240539188
Principal investigator 1 Incyte Corporation $1,371.00 06/25/2025 Non-covered Recipient Entity
INNOVATIVE CLINICAL RESEARCH INSTITUTE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240539209
Principal investigator 1 Incyte Corporation $2,223.00 06/25/2025 Non-covered Recipient Entity
INNOVATIVE CLINICAL RESEARCH INSTITUTE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240539221
Principal investigator 1 ABBVIE INC. $2,316.60 06/17/2025 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202491761
Principal investigator 1 Incyte Corporation $2,237.00 06/12/2025 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240527038
Principal investigator 1 Incyte Corporation $525.00 06/04/2025 Non-covered Recipient Entity
INNOVATIVE CLINICAL RESEARCH INSTITUTE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240539176
Principal investigator 1 Incyte Corporation $600.00 06/04/2025 Non-covered Recipient Entity
INNOVATIVE CLINICAL RESEARCH INSTITUTE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240539192
Principal investigator 1 Incyte Corporation $2,413.00 06/04/2025 Non-covered Recipient Entity
INNOVATIVE CLINICAL RESEARCH INSTITUTE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240539197
Principal investigator 1 Incyte Corporation $3,098.00 06/04/2025 Non-covered Recipient Entity
INNOVATIVE CLINICAL RESEARCH INSTITUTE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240539200
Principal investigator 1 ABBVIE INC. $2,148.50 06/03/2025 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202488205
Principal investigator 1 Incyte Corporation $4,970.00 06/03/2025 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
An Open-Label, Single-Arm, Phase 4 Study of Ruxolitinib Cream in Adults With Atopic Dermatitis Experiencing Sleep Disturbance in the United States (MORPHEUS) No dispute reported 06/30/2026 1240526799
Principal investigator 1 Incyte Corporation $24.72 06/03/2025 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240526863
Principal investigator 1 Incyte Corporation $6,000.00 05/28/2025 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib No dispute reported 06/30/2026 1240526780
Principal investigator 1 Incyte Corporation $1,500.00 05/28/2025 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib No dispute reported 06/30/2026 1240526784
Principal investigator 1 ABBVIE INC. $972.84 05/22/2025 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202485859
Principal investigator 1 Incyte Corporation $1,726.50 05/21/2025 Non-covered Recipient Entity
INNOVATIVE CLINICAL RESEARCH INSTITUTE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240539172
Principal investigator 1 Incyte Corporation $1,371.00 05/21/2025 Non-covered Recipient Entity
INNOVATIVE CLINICAL RESEARCH INSTITUTE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240539213
Principal investigator 1 Incyte Corporation $1,371.00 05/21/2025 Non-covered Recipient Entity
INNOVATIVE CLINICAL RESEARCH INSTITUTE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240539217
Principal investigator 1 Incyte Corporation $46.62 05/15/2025 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240527034
Principal investigator 1 Incyte Corporation $1,894.00 05/08/2025 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240527030
Principal investigator 1 ABBVIE INC. $23,691.90 05/07/2025 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202483329
Principal investigator 1 Incyte Corporation $124.54 05/02/2025 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240526816
Principal investigator 1 Incyte Corporation $118.26 05/02/2025 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240526845
Principal investigator 1 Incyte Corporation $48.54 05/02/2025 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240526847
Principal investigator 1 Incyte Corporation $45.80 05/02/2025 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240526855
Principal investigator 1 Incyte Corporation $62.27 05/02/2025 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240526859
Principal investigator 1 Incyte Corporation $1,371.00 05/02/2025 Non-covered Recipient Entity
INNOVATIVE CLINICAL RESEARCH INSTITUTE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240539157
Principal investigator 1 Incyte Corporation $1,500.00 05/02/2025 Non-covered Recipient Entity
INNOVATIVE CLINICAL RESEARCH INSTITUTE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240539180
Principal investigator 1 Incyte Corporation $946.80 05/02/2025 Non-covered Recipient Entity
INNOVATIVE CLINICAL RESEARCH INSTITUTE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240539224
Principal investigator 1 ABBVIE INC. $23.86 05/01/2025 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202480785
Principal investigator 1 ABBVIE INC. $2,164.50 04/17/2025 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202477465
Principal investigator 1 Incyte Corporation $23.04 04/15/2025 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240527025
Principal investigator 1 ABBVIE INC. $14,362.30 04/03/2025 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202470877
Principal investigator 1 ABBVIE INC. $33.73 04/03/2025 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202471106
Principal investigator 1 Incyte Corporation $4.24 04/02/2025 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240526803
Principal investigator 1 Incyte Corporation $16.44 04/02/2025 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240526808
Principal investigator 1 Incyte Corporation $37.10 04/02/2025 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240526812
Principal investigator 1 Incyte Corporation $8.24 04/02/2025 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240526821
Principal investigator 1 Incyte Corporation $11.33 04/02/2025 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240526824
Principal investigator 1 Incyte Corporation $16.14 04/02/2025 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240526828
Principal investigator 1 Incyte Corporation $249.10 04/02/2025 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240526831
Principal investigator 1 Incyte Corporation $16.48 04/02/2025 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240526836
Principal investigator 1 Incyte Corporation $47.70 04/02/2025 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240526840
Principal investigator 1 Incyte Corporation $53.80 04/02/2025 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240526851
Principal investigator 1 Incyte Corporation $100.70 04/02/2025 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240526866
Principal investigator 1 Incyte Corporation $31.80 04/02/2025 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240526871
Principal investigator 1 Incyte Corporation $54.76 04/02/2025 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240526875
Principal investigator 1 Incyte Corporation $21.20 04/02/2025 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240526879
Principal investigator 1 Incyte Corporation $16.44 04/02/2025 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240526883
Principal investigator 1 Incyte Corporation $16.44 04/02/2025 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240526887
Principal investigator 1 Incyte Corporation $16.44 04/02/2025 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240526890
Principal investigator 1 Incyte Corporation $16.14 04/02/2025 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240526898
Principal investigator 1 Incyte Corporation $2,094.00 04/02/2025 Non-covered Recipient Entity
INNOVATIVE CLINICAL RESEARCH INSTITUTE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240539148
Principal investigator 1 Incyte Corporation $1,371.00 04/02/2025 Non-covered Recipient Entity
INNOVATIVE CLINICAL RESEARCH INSTITUTE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240539152
Principal investigator 1 Incyte Corporation $1,371.00 04/02/2025 Non-covered Recipient Entity
INNOVATIVE CLINICAL RESEARCH INSTITUTE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240539160
Principal investigator 1 Incyte Corporation $1,500.00 04/02/2025 Non-covered Recipient Entity
INNOVATIVE CLINICAL RESEARCH INSTITUTE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240539164
Principal investigator 1 Incyte Corporation $1,367.10 04/02/2025 Non-covered Recipient Entity
INNOVATIVE CLINICAL RESEARCH INSTITUTE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240539168
Principal investigator 1 Incyte Corporation $4,980.50 04/02/2025 Non-covered Recipient Entity
INNOVATIVE CLINICAL RESEARCH INSTITUTE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240539205
Principal investigator 1 Incyte Corporation $2,097.00 04/01/2025 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240527013
Principal investigator 1 Incyte Corporation $1,000.00 04/01/2025 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240527017
Principal investigator 1 Incyte Corporation $1,000.00 04/01/2025 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240527021
Principal investigator 1 Incyte Corporation $4,005.00 03/25/2025 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240527009
Principal investigator 1 ABBVIE INC. $22,397.60 03/07/2025 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
M20-465 - A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202461164
Principal investigator 1 Incyte Corporation $8.48 03/03/2025 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240526727
Principal investigator 1 Incyte Corporation $98.72 03/03/2025 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240526731
Principal investigator 1 Incyte Corporation $49.36 03/03/2025 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240526735
Principal investigator 1 Incyte Corporation $32.88 03/03/2025 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240526743
Principal investigator 1 Incyte Corporation $32.88 03/03/2025 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240526752
Principal investigator 1 Incyte Corporation $57.25 03/03/2025 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240526756
Principal investigator 1 Incyte Corporation $32.88 03/03/2025 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240526760
Principal investigator 1 Incyte Corporation $32.88 03/03/2025 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240526764
Principal investigator 1 Incyte Corporation $1,371.00 03/03/2025 Non-covered Recipient Entity
INNOVATIVE CLINICAL RESEARCH INSTITUTE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240539108
Principal investigator 1 Incyte Corporation $2,223.00 03/03/2025 Non-covered Recipient Entity
INNOVATIVE CLINICAL RESEARCH INSTITUTE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240539120
Principal investigator 1 Incyte Corporation $1,371.00 03/03/2025 Non-covered Recipient Entity
INNOVATIVE CLINICAL RESEARCH INSTITUTE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240539125
Principal investigator 1 Incyte Corporation $737.40 03/03/2025 Non-covered Recipient Entity
INNOVATIVE CLINICAL RESEARCH INSTITUTE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240539144
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $9,000.00 02/24/2025 Non-covered Recipient Entity
Dermatology Specialists Inc-Oceanside
Randomised, double-blind, placebo-controlled, Phase IIb/Phase III study to evaluate the efficacy and safety of spesolimab in patients with moderate to severe hidradenitis suppurativa. Lunsayil 1. No dispute reported 06/30/2026 1220795755
Principal investigator 1 Incyte Corporation $365.21 02/12/2025 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by a Long-Term Safety Extension Period in Children (Ages 2 Years to 12 Years) With Atopic Dermatitis (TRuE-AD3) No dispute reported 06/30/2026 1240526791
Principal investigator 1 ABBVIE INC. $31,784.70 02/06/2025 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
M20-465 - A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202449906
Principal investigator 1 ABBVIE INC. $1,526.20 02/05/2025 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
M20-465 - A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202446341
Principal investigator 1 Eli Lilly and Company $198,777.97 02/05/2025 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A PHASE 2B, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE ELTREKIBART IN ADULT PARTICIPANTS WITH MODERATE TO SEVERE HIDRADENITIS SUPPURATIVA No dispute reported 06/30/2026 1187878737
Principal investigator 1 Incyte Corporation $184.00 02/05/2025 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
An Open-Label, Single-Arm, Phase 4 Study of Ruxolitinib Cream in Adults With Atopic Dermatitis Experiencing Sleep Disturbance in the United States (MORPHEUS) No dispute reported 06/30/2026 1240526795
Principal investigator 1 Incyte Corporation $2,000.00 02/05/2025 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240527067
Principal investigator 1 Incyte Corporation $9,000.00 02/05/2025 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240527072
Principal investigator 1 Incyte Corporation $2,094.00 01/27/2025 Non-covered Recipient Entity
INNOVATIVE CLINICAL RESEARCH INSTITUTE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240539094
Principal investigator 1 Incyte Corporation $2,094.00 01/27/2025 Non-covered Recipient Entity
INNOVATIVE CLINICAL RESEARCH INSTITUTE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240539098
Principal investigator 1 Incyte Corporation $1,371.00 01/27/2025 Non-covered Recipient Entity
INNOVATIVE CLINICAL RESEARCH INSTITUTE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240539129
Principal investigator 1 Incyte Corporation $540.90 01/27/2025 Non-covered Recipient Entity
INNOVATIVE CLINICAL RESEARCH INSTITUTE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240539134
Principal investigator 1 Incyte Corporation $540.90 01/27/2025 Non-covered Recipient Entity
INNOVATIVE CLINICAL RESEARCH INSTITUTE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240539139
Principal investigator 1 Incyte Corporation $3,980.22 01/23/2025 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by a Long-Term Safety Extension Period in Children (Ages 2 Years to 12 Years) With Atopic Dermatitis (TRuE-AD3) No dispute reported 06/30/2026 1240526787
Principal investigator 1 ABBVIE INC. $1,153.10 01/15/2025 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
M20-465 - A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202438713
Principal investigator 1 Incyte Corporation $2,094.00 01/15/2025 Non-covered Recipient Entity
INNOVATIVE CLINICAL RESEARCH INSTITUTE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240539085
Principal investigator 1 Incyte Corporation $1,371.00 01/15/2025 Non-covered Recipient Entity
INNOVATIVE CLINICAL RESEARCH INSTITUTE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240539090
Principal investigator 1 Incyte Corporation $688.00 01/15/2025 Non-covered Recipient Entity
INNOVATIVE CLINICAL RESEARCH INSTITUTE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240539102
Principal investigator 1 Incyte Corporation $2,094.00 01/15/2025 Non-covered Recipient Entity
INNOVATIVE CLINICAL RESEARCH INSTITUTE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240539104
Principal investigator 1 Incyte Corporation $1,371.00 01/15/2025 Non-covered Recipient Entity
INNOVATIVE CLINICAL RESEARCH INSTITUTE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240539112
Principal investigator 1 Incyte Corporation $1,371.00 01/15/2025 Non-covered Recipient Entity
INNOVATIVE CLINICAL RESEARCH INSTITUTE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240539116
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $15,812.16 01/03/2025 Non-covered Recipient Entity
Dermatology Specialists Of Spokane
A Phase 2b, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled 54-Week Study to Evaluate the Efficacy and Safety of Rezpegaldesleukin in the Treatment of Adult Patients with Moderate-to-Severe Atopic Dermatitis No dispute reported 06/30/2026 1235997693
Principal investigator 1 ABBVIE INC. $1,153.10 01/02/2025 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
M20-465 - A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202435035
Principal investigator 1 Incyte Corporation $31.93 01/02/2025 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240526719
Principal investigator 1 Incyte Corporation $21.63 01/02/2025 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240526723
Principal investigator 1 Incyte Corporation $4.24 01/02/2025 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240526739
Principal investigator 1 Incyte Corporation $16.44 01/02/2025 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240526748
Principal investigator 1 Incyte Corporation $16.44 01/02/2025 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240526768
Principal investigator 1 Incyte Corporation $16.44 01/02/2025 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240526772
Principal investigator 1 Incyte Corporation $16.44 01/02/2025 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240526776